Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Empagliflozin/Linagliptin/Metformin XR FDC Tablets
NCT02821910Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin, linagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to Last Quantifiable Concentration, Maximum Measured Concentration and 1 more. Started Jul 2016; status: completed.
02
Drugs
empagliflozinlinagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02821910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821910.